Product Information
RELAFEN DS 1,000 MG TABLET is a brand (anda) product labeled by CarWin Pharmaceutical Associates LLC, priced at $31.6667 per EA under NDC 15370017060. Its NADAC has been published 42 times since Dec 17, 2025.
FDA first approved this application on Aug 30, 2019. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the NABUMETONE market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
1000 mg/1
Manufacturer
CarWin Pharmaceutical Associates LLCNDC
15370017060
Classification
Brand (ANDA)
Dosage Form
TABLET
Route
ORAL
Effective Date
6/17/2026
Active Ingredients
NABUMETONEApproval Type
Generic (ANDA)
FDA Application
ANDA203166FDA Approved
8/30/2019
TE Code
AB
On Market Since
9/20/2019
Pharmacological Classes
Price Statistics
The NADAC for RELAFEN DS 1,000 MG TABLET has been published 42 times since Dec 17, 2025, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $31.6667 per EA |
|---|---|
| All-time high | $31.6667 (Sep 30, 2026) |
| All-time low | $31.6667 (Dec 17, 2025) |
| 52-week high | $31.6667 |
| 52-week low | $31.6667 |
| Median price | $31.6667 |
| Average price | $31.6667 |
| Largest weekly change | 0.0% (Dec 24, 2025) |
| Weeks tracked | 42 |
| Tracking since | Dec 17, 2025 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
CarWin Pharmaceutical Associates LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
NABUMETONE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Nonsteroidal Anti-inflammatory Drug class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of RELAFEN DS 1,000 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for RELAFEN DS 1,000 MG TABLET, manufactured by CarWin Pharmaceutical Associates LLC, is $31.6667 per EA (NDC 15370017060), effective Sep 30, 2026.
How has the price of RELAFEN DS 1,000 MG TABLET changed over time?
Over the history we have for it, the NADAC for RELAFEN DS 1,000 MG TABLET has held within roughly two percent of its current level. It has been tracked across 42 weekly CMS publications since Dec 17, 2025.
What are the highest and lowest recorded NADAC prices for RELAFEN DS 1,000 MG TABLET?
Since Dec 17, 2025, the NADAC for RELAFEN DS 1,000 MG TABLET has ranged from a low of $31.6667 (Dec 17, 2025) to a high of $31.6667 (Sep 30, 2026), with a median of $31.6667 per EA.
Are there cheaper alternatives to RELAFEN DS 1,000 MG TABLET?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as RELAFEN DS 1,000 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures RELAFEN DS 1,000 MG TABLET?
RELAFEN DS 1,000 MG TABLET (NDC 15370017060) is labeled by CarWin Pharmaceutical Associates LLC, and CMS classifies it as a brand (anda) product.